Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections.
Open accessThe DOI matches its Crossref record; 695 of the 697 references it cites were found in a registry or an index.
Abstract
Background: The Infectious Diseases Society of America is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant infections. This guidance document focuses on infections caused by extended-spectrum β-lactamase–producing Enterobacterales, AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa with difficult-to-treat resistance, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia. This updated document replaces previous versions of the guidance document. Methods: A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections formulated questions about the treatment of infections caused by extended-spectrum β-lactamase-producing Enterobacterales, AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa with difficult-to-treat resistance, carbapenem-resistant Acinetobacter baumannii, and S. maltophilia. Because of differences in the epidemiology of resistance and availability of specific anti-infectives internationally, this document focuses on the treatment of infections in the United States. Results: Preferred and alternative suggested treatment approaches are provided with accompanying rationales, assuming the causative organism has been identified and antibiotic susceptibility results are known. Approaches to empiric treatment, transitioning to oral therapy, duration of therapy, and other management considerations are also discussed briefly. Suggested approaches apply for both adult and pediatric populations, although suggested antibiotic dosages are provided only for adults. Conclusions: The field of antimicrobial-resistance is highly dynamic. Consultation with an infectious diseases specialist is recommended for the treatment of antimicrobial resistant infections. This document is current as of 31 December 2022 and will be updated periodically. The most current version of this document, including date of publication, is available at www.idsociety.org/practice-guideline/amr-guidance/.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Items 401–600 of 695
Beganovic, M., Daffinee, K. E., Luther, M. K., & LaPlante, K. L. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01680-20 · Cited by 61
Alosaimy, S., Lagnf, A. M., Morrisette, T., Scipione, M. R., Zhao, J. J., Jorgensen, S. C. J., Mynatt, R. P., Carlson, T. J., Jo, J., Garey, K. W., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab371 · Cited by 61
Räisänen, K., Koivula, I., Ilmavirta, H., Puranen, S., Kallonen, T., Lyytikäinen, O., & Jalava, J. (2019) · Eurosurveillance · doi:10.2807/1560-7917.es.2019.24.19.1900256 · Cited by 60
Tamma, P. D., Sharara, S. L., Pana, Z. D., Amoah, J., Fisher, S. L., Tekle, T., Doi, Y., & Simner, P. J. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz353 · Cited by 60
Self-citationLob, S. H., Karlowsky, J. A., Young, K., Motyl, M. R., Hawser, S., Kothari, N. D., & Sahm, D. F. (2020) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001142 · Cited by 60
Sarzynski, S. H., Warner, S., Sun, J., Matsouaka, R., Dekker, J. P., Babiker, A. Y. M., Li, W., Lai, Y. L., Danner, R. L., Fowler, V. G., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab644 · Cited by 60
Fosfomycin for Treatment of Prostatitis: New Tricks for Old Dogs: Figure 1.
Grayson, M. L., Maćešić, N., Trevillyan, J. M., Ellis, A. G., Zeglinski, P. T., Hewitt, N. H., Gardiner, B. J., & Frauman, A. G. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ436 · Cited by 59
Kuo, S., Lee, Y.-T., Yang, S.-P., Chen, C.-P., Chen, T.-L., Hsieh, S.-L., Siu, L.-K. K., & Fung, C. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03682.x · Cited by 58
Chen, Z., & Shi, X. (2018) · Medicine · doi:10.1097/md.0000000000012467 · Cited by 58
Niu, T., Luo, Q., Li, Y., Zhou, Y., Yu, W., & Xiao, Y. (2019) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-019-0502-x · Cited by 58
Flamm, R. K., Shortridge, D., Castanheira, M., Sader, H. S., & Pfaller, M. A. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01154-19 · Cited by 58
Assimakopoulos, S. F., Karamouzos, V., Lefkaditi, A., Sklavou, C., Kolonitsiou, F., Christofidou, M., Fligou, F., Gogos, C. A., & Marangos, M. N. (2019) · PubMed · Cited by 58
O’Donnell, J. N., Putra, V., & Lodise, T. P. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2607 · Cited by 58
Pogue, J. M., Neelakanta, A., Mynatt, R. P., Sharma, S., Lephart, P., & Kaye, K. S. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu594 · Cited by 57
Barnaud, G., Benzerara, Y., Gravisse, J., Raskine, L., Pors, M.-J. S.-L., Labia, R., & Arlet, G. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.1040-1042.2004 · Cited by 57
Karlowsky, J. A., Lob, S. H., Young, K., Motyl, M. R., & Sahm, D. F. (2018) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2018.07.012 · Cited by 57
Omadacycline: A Review of the Clinical Pharmacokinetics and Pharmacodynamics
Rodvold, K. A., Burgos, R. M., Tan, X., & Pai, M. P. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00843-4 · Cited by 57
Activity of Cefiderocol and Comparators against Isolates from Cancer Patients
Rolston, K. V. I., Gerges, B., Shelburne, S. A., Aitken, S. L., RAAD, I. I., & Prince, R. A. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01955-19 · Cited by 57
Self-citationInhaled colistin as monotherapy for multidrug-resistant gram (−) nosocomial pneumonia: A case series
Falagas, M. E., Siempos, I. Ι., Rafailidis, P. I., Korbila, I. P., Ioannidou, E., & Michalopoulos, A. S. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2008.11.018 · Cited by 56
Lin, C.-C., Liu, T.-C., Kuo, C.-F., Liu, C.-P., & Lee, C.-M. (2010) · Journal of Microbiology Immunology and Infection · doi:10.1016/s1684-1182(10)60050-3 · Cited by 56
Harris, P. N. A., Mo, Y., Jureen, R., Chew, J., Ali, J., Paynter, S., Paterson, D. L., & Tambyah, P. A. (2015) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-015-0055-6 · Cited by 56
Amat, T., Gutiérrez-Pizarraya, A., Machuca, I., Gracia-Ahufinger, I., Pérez‐Nadales, E., Torre‐Giménez, Á., Garnacho‐Montero, J., Cisneros, J. M., & Torre‐Cisneros, J. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.09.016 · Cited by 56
Oral fosfomycin for the treatment of chronic bacterial prostatitis
Karaiskos, I., Galani, L., Sakka, V., Gkoufa, A., Sopilidis, O., Chalikopoulos, D., Alivizatos, G. J., & Giamarellou, E. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz015 · Cited by 56
Early Experience With Eravacycline for Complicated Infections
Alosaimy, S., Molina, K. C., Claeys, K. C., Andrade, J., Truong, J. Q., King, M. A., Pullinger, B. M., Huang, G., Morrisette, T., Lagnf, A. M., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa071 · Cited by 56
Sabour, S., Huang, J. Y., Bhatnagar, A. S., Gilbert, S. E., Karlsson, M., Lonsway, D., Lutgring, J. D., Rasheed, J. K., Halpin, A. L., Stanton, R. A., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01105-21 · Cited by 56
Alosaimy, S., Morrisette, T., Lagnf, A. M., Rojas, L. M., King, M. A., Pullinger, B. M., Hobbs, A. L. V., Perkins, N. B., Veve, M. P., Bouchard, J., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00479-22 · Cited by 56
García‐León, G., Puig, C. R. D. A., de la Fuente, C. G., Martínez-Martínez, L., Martínez, J. L., & Sánchez, M. B. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.01.007 · Cited by 55
Towfigh, S., Pasternak, J., Poirier, A., Leister, H., & Babinchak, T. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03122.x · Cited by 55
Sorlí, L., Luque, S., Li, J., Campillo, N., Danés-Castells, M., Montero, M., Segura, C., Grau, S., & Horcajada, J. P. (2019) · Journal of Infection · doi:10.1016/j.jinf.2019.06.011 · Cited by 55
Ku, N. S., Lee, S.-H., Lim, Y. S., Choi, H., Ahn, J. Y., Jeong, S. J., Shin, S. J., Choi, J. Y., Choi, Y. H., Yeom, J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-53714-0 · Cited by 55
Zhou, M., Wang, Y., Liu, C., Kudinha, T., Liu, X., Luo, Y., Yang, Q., Sun, H., Hu, J., & Xu, Y. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s166790 · Cited by 54
Alosaimy, S., Jorgensen, S. C. J., Lagnf, A. M., Melvin, S. M., Mynatt, R. P., Carlson, T. J., Garey, K. W., Allen, D., Venugopalan, V., Veve, M. P., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa051 · Cited by 54
Tselepis, L., Langley, G. W., Aboklaish, A. F., Widlake, E., Jackson, D. E., Walsh, T. R., Schofield, C. J., Brem, J., & Tyrrell, J. M. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105925 · Cited by 54
Tada, K., Kurosawa, S., Hiramoto, N., Okinaka, K., Ueno, N., Asakura, Y., Kim, S.-W., Yamashita, T., Mori, S.-I., Heike, Y., et al. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.87 · Cited by 53
Lob, S. H., Hackel, M., Kazmierczak, K. M., Hoban, D. J., Young, K., Motyl, M. R., Karlowsky, J. A., & Sahm, D. F. (2017) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2017.02.018 · Cited by 53
Shortridge, D., Pfaller, M. A., Castanheira, M., & Flamm, R. K. (2017) · Microbial Drug Resistance · doi:10.1089/mdr.2017.0266 · Cited by 53
Sader, H. S., Flamm, R. K., Carvalhaes, C. G., & Castanheira, M. (2019) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2019.05.005 · Cited by 53
Nys, C., Cherabuddi, K., Venugopalan, V., & Klinker, K. P. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00788-19 · Cited by 53
Cano, Á., Guzmán-Puche, J., García‐Gutiérrez, M., Castón, J. J., Gracia-Ahufinger, I., Pérez‐Nadales, E., Recio, M., Natera, A. M., Marfil, E., Martı́nez-Martı́nez, L., et al. (2019) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2019.11.007 · Cited by 53
In Vitro Activity and In Vivo Efficacy of Cefiderocol against Stenotrophomonas maltophilia
Nakamura, R., Oota, M., Matsumoto, S., Sato, T., & Yamano, Y. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01436-20 · Cited by 53
Gordon, N. C., & Wareham, D. W. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp476 · Cited by 52
Karlowsky, J. A., Lob, S. H., Kazmierczak, K. M., Young, K., Motyl, M. R., & Sahm, D. F. (2019) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2019.10.028 · Cited by 52
Tamma, P. D., Smith, T. T., Adebayo, A., Karaba, S. M., Jacobs, E. B., Wakefield, T., Nguyen, T. H. D., Whitfield, N. N., & Simner, P. J. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00127-21 · Cited by 52
Self-citationAcinetobacter baumannii and Cefiderocol, between Cidality and Adaptability
Stracquadanio, S., Bonomo, C., Marıno, A., Bongiorno, D., Privitera, G. F., Bivona, D. A., Mirabile, A., Bonacci, P. G., & Stefani, S. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02347-22 · Cited by 52
Sader, H. S., Flamm, R. K., Dale, G. E., Rhomberg, P. R., & Castanheira, M. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky227 · Cited by 51
Kim, S., Cha, M. K., Kang, C., Ko, J., Huh, K., Cho, S. Y., Chung, D. R., & Peck, K. R. (2018) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-018-3425-1 · Cited by 51
Zamudio, R., Hijazi, K., Joshi, C., Aitken, E., Oggioni, M. R., & Gould, I. M. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.02.022 · Cited by 51
Shah, M. D., Coe, K. E., Boghdadly, Z. E., Wardlow, L. C., Dela‐Pena, J., Stevenson, K., & Reed, E. E. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz116 · Cited by 51
Chen, J., Liang, Q., Chen, X., Wu, J., Wu, Y., Teng, G., & Huang, M. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s350976 · Cited by 51
Castanheira, M., Kimbrough, J. H., DeVries, S. D., Mendes, R. E., & Sader, H. S. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad038 · Cited by 51
Sulbactam: a beta-lactamase inhibitor.
Noguchi, J. K., & Gill, M. A. (1988) · PubMed · Cited by 50
Pfaller, M. A., Shortridge, D., Sader, H. S., Gales, A. C., Castanheira, M., & Flamm, R. K. (2017) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2017.06.008 · Cited by 50
Canver, M. C., Satlin, M. J., Westblade, L. F., Kreiswirth, B. N., Chen, L., Robertson, A., Fauntleroy, K. A., Spina, M. L., Callan, K., & Jenkins, S. G. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00672-19 · Cited by 50
Benchetrit, L., Mathy, V., Armand-Lefèvre, L., Bouadma, L., & Timsit, J. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.10.023 · Cited by 50
Lodise, T. P., Wart, S. V., Sund, Z. M., Bressler, A. M., Khan, A., Makley, A. T., Hamad, Y., Salata, R. A., Silveira, F. P., Sims, M. D., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01809-20 · Cited by 50
Cefepime MIC as a Predictor of the Extended-Spectrum β-Lactamase Type inKlebsiella pneumoniae,Taiwan
Yu, W. L., Pfaller, M. A., Winokur, P. L., & Jones, R. N. (2002) · Emerging infectious diseases · doi:10.3201/eid0805.010346 · Cited by 49
Crandon, J. L., Kim, A., & Nicolau, D. P. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp301 · Cited by 49
Ba, B. B., Feghali, H., Arpin, C., Saux, M., & Quentin, C. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.946-953.2004 · Cited by 49
Nucleotide sequence of the ampC-ampR region from the chromosome of Yersinia enterocolitica
Seoane, A., Francia, M. V., & Lobo, J. M. G. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.5.1049 · Cited by 49
Yang, Y., Lee, Y., Tseng, K.-C., Huang, W., Chuang, M.-F., Kuo, S., Lauderdale, T.-L. Y., & Chen, T.-L. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02994-15 · Cited by 49
Elliott, Z. S., Barry, K. E., Cox, H. L., Stoesser, N. E., Carroll, J., Vegesana, K. B., Kotay, S. M., Sheppard, A. E., Wailan, A. M., Crook, D. W., et al. (2019) · Journal of Clinical Microbiology · doi:10.1128/jcm.00634-19 · Cited by 49
Self-citationGolden, A., Adam, H. J., Baxter, M. R., Walkty, A. J., Lagacé-Wiens, P. R. S., Karlowsky, J. A., & Zhanel, G. G. (2020) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2020.115012 · Cited by 49
Zusman, O., Farbman, L., Tredler, Z., Daitch, V., Lador, A., Leibovici, L., & Paul, M. (2014) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2014.08.003 · Cited by 48
Tsai, H.-Y., Chen, Y., Tang, H.-J., Huang, C.-C., Liao, C., Chu, F., Chuang, Y.-C., Sheng, W., Ko, W., & Hsueh, P. (2014) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.07.006 · Cited by 48
Avery, L. M., & Nicolau, D. P. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.07.011 · Cited by 48
Carvalhaes, C. G., Castanheira, M., Sader, H. S., Flamm, R. K., & Shortridge, D. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2018.11.021 · Cited by 48
Gaibani, P., Bianco, G., Amadesi, S., Boattini, M., Ambretti, S., & Costa, C. S. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00191-22 · Cited by 48
Karlowsky, J. A., Lob, S. H., DeRyke, C. A., Hilbert, D. W., Wong, M. T., Young, K., Siddiqui, F., Motyl, M. R., & Sahm, D. F. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00189-22 · Cited by 48
Penicillin-binding proteins and induction of AmpC beta-lactamase
Sanders, C. C., Bradford, P. A., Ehrhardt, A. F., Bush, K., Young, K. D., Henderson, T. A., & Sanders, W. E. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.9.2013 · Cited by 47
Yoon, Y. K., Kim, J. H., Sohn, J. W., Yang, K., & Kim, M. J. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.12.017 · Cited by 47
Khalili, H., Shojaei, L., Mohammadi, M., Beigmohammadi, M. T., Abdollahi, A., & Doomanlou, M. (2018) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2018-0037 · Cited by 47
Collaborators, O. B. O. T. S., Galani, I., Souli, M., Nafplioti, K., Adamou, P., Karaiskos, I., Giamarellou, H., & Antoniadou, A. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03517-y · Cited by 47
Sader, H. S., Duncan, L. R., Arends, S. J. R., Carvalhaes, C. G., & Castanheira, M. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01433-20 · Cited by 47
Enhancing Resistance to Cephalosporins in Class C β-Lactamases: Impact of Gly214Glu in CMY-2
Endimiani, A., Doi, Y., Bethel, C. R., Taracila, M. A., Adams‐Haduch, J. M., O’Keefe, A., Hujer, A. M., Paterson, D. L., Skalweit, M. J., Page, M. G. P., et al. (2009) · Biochemistry · doi:10.1021/bi9015549 · Cited by 46
Self-citationMurano, K., Yamanaka, T., Toda, A., Ohki, H., Okuda, S., Kawabata, K., Hatano, K., Takeda, S., Akamatsu, H., Itoh, K., et al. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.11.074 · Cited by 46
Şimşek, F., Gedık, H., Yıldırmak, T., İris, N., Türkmen, A., Ersoy, A., Ersöz, M., & Gücüyener, A. (2012) · Indian Journal of Medical Microbiology · doi:10.4103/0255-0857.103767 · Cited by 46
Failure of Cefepime Therapy in Treatment of Klebsiella pneumoniae Bacteremia
Song, W., Moland, E. S., Hanson, N. D., Lewis, J. S., Jorgensen, J. H., & Thomson, K. S. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.9.4891-4894.2005 · Cited by 46
Jang, J. Y., Kwon, H. Y., Choi, E. H., Lee, W., Shim, H., & Bae, K. S. (2017) · Journal of Critical Care · doi:10.1016/j.jcrc.2017.04.004 · Cited by 46
Balabanian, G., Rose, M., Manning, N., Landman, D., & Quale, J. M. (2018) · Microbial Drug Resistance · doi:10.1089/mdr.2018.0065 · Cited by 46
Karlowsky, J. A., Lob, S. H., Kazmierczak, K. M., Young, K., Motyl, M. R., & Sahm, D. F. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00169-18 · Cited by 46
Characterization of carbapenem-resistant but cephalosporin-susceptible Pseudomonas aeruginosa
Khalili, Y., Yekani, M., Goli, H. R., & Memar, M. Y. (2019) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/030.66.2019.036 · Cited by 46
Tan, S. H., Ng, T. M., Chew, K. L., Yong, J., Wu, J. E., Yap, M. Y., Heng, S. T., Ng, W. H. W., Shilin, W., Cheok, S. J. H., et al. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.105860 · Cited by 46
Lee, M., Abbey, T. C., Biagi, M. J., & Wenzler, E. (2020) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2020.115227 · Cited by 46
Kuo, S., Wang, Y.-C., Tan, M.-C., Huang, W., Shiau, Y., Wang, H., Lai, J., Huang, I., & Lauderdale, T.-L. Y. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab141 · Cited by 46
Tamma, P. D., Harris, P. N. A., Mathers, A. J., Wenzler, E., & Humphries, R. M. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac688 · Cited by 46
Self-citationFosfomycin for bacterial prostatitis: a review
Kwan, A. C. F., & Beahm, N. P. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106106 · Cited by 45
Evaluating Metabolic Pathways and Biofilm Formation in Stenotrophomonas maltophilia
Isom, C. M., Fort, B., & Anderson, G. G. (2021) · Journal of Bacteriology · doi:10.1128/jb.00398-21 · Cited by 45
Tigecycline as a therapeutic option inStenotrophomonas maltophiliainfections
Tekce, Y. T., Erbay, A., Çabadak, H., & Şen, S. (2012) · Journal of Chemotherapy · doi:10.1179/1120009x12z.00000000022 · Cited by 44
Lim, S.-K., Lee, S., Choi, S., Choi, J., Kim, S., Jeong, J., Choi, S., Woo, J. H., & Kim, Y. S. (2011) · Journal of Korean Medical Science · doi:10.3346/jkms.2011.26.3.325 · Cited by 44
Mechanisms of carbapenem resistance in cephalosporin-susceptible Pseudomonas aeruginosa in China
Zeng, Z., Wang, W., Huang, M., Shi, L.-N., Wang, Y., & Shao, H. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2013.11.014 · Cited by 44
Araoka, H., Fujii, T., Izutsu, K., Kimura, M., Nishida, A., Ishiwata, K., Nakano, N., Tsuji, M., Yamamoto, H., Asano‐Mori, Y., et al. (2012) · Transplant Infectious Disease · doi:10.1111/j.1399-3062.2011.00710.x · Cited by 44
Campana, E. H., Xavier, D. E., Petrolini, F. V. B., Cordeiro-Moura, J. R., de Araújo, M. R. E., & Gales, A. C. (2016) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2016.10.008 · Cited by 44
Pfaller, M. A., Shortridge, D., Sader, H. S., Castanheira, M., & Flamm, R. K. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.09.016 · Cited by 44
Johnston, B., THURAS, P. D., Porter, S. B., Anacker, M. L., VonBank, B., Vagnone, P. S., Witwer, M. L., Castanheira, M., & Johnson, J. R. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00797-20 · Cited by 44
Khan, A., Arias, C. A., Abbott, A., Bard, J. D., Bhatti, M. M., & Humphries, R. M. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00654-21 · Cited by 44
Scott, C. J., Zhu, E., Jayakumar, R. A., Shan, G., & Viswesh, V. V. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280221085551 · Cited by 44
Yang, C., Li, S.-H., Chuang, F., Chen, C., Lee, C.-H., Chen, J., Wu, C., & Lee, C. (2012) · BMC Infectious Diseases · doi:10.1186/1471-2334-12-206 · Cited by 43
Pseudomonas aeruginosa Susceptible Only to Colistin in Intensive Care Unit Patients
Mastoraki, A. T., Douka, E., Kriaras, I., Stravopodis, G., Manoli, H., & Geroulanos, S. (2008) · Surgical Infections · doi:10.1089/sur.2007.004 · Cited by 43
Bonfiglio, G. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/45.1.115 · Cited by 43
Antibacterial in vitro activity of fourth generation cephalosporins.
Hancock, R. E. W., & Bellido, F. (1996) · PubMed · Cited by 43
Lob, S. H., Hoban, D. J., Young, K., Motyl, M. R., & Sahm, D. F. (2018) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2018.05.017 · Cited by 43
Trebosc, V., Schellhorn, B., Schill, J., Lucchini, V., Bühler, J., Bourotte, M., Butcher, J. J., Gitzinger, M., Lociuro, S., Kemmer, C., et al. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa370 · Cited by 43
Duffy, N., Karlsson, M., Reses, H. E., Campbell, D., Daniels, J., Stanton, R. A., Janelle, S. J., Schutz, K., Bamberg, W., Rebolledo, P. A., et al. (2022) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.496 · Cited by 43
Sempere, A., Viñado, B., Arcos, I. L., Campany, D., Larrosa, N., Fernández‐Hidalgo, N., Rodríguez-Pardo, D., González‐López, J. J., Nuvials, X., Almirante, B., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00751-22 · Cited by 43
Mendes, R. E., Castanheira, M., Woosley, L. N., Stone, G. G., Bradford, P. A., & Flamm, R. K. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02447-16 · Cited by 42
Kim, Y. K., Lee, J. H., Lee, H.-K., Chung, B. C., Yu, S. J., Lee, H., Park, J. H., Kim, S., Kim, H.-K., Kiem, S., et al. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.02.61 · Cited by 42
Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015–17
Lob, S. H., Karlowsky, J. A., Young, K., Motyl, M. R., Hawser, S., Kothari, N., Gueny, M. E., & Sahm, D. F. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz191 · Cited by 42
Lee, C., Su, L., Chen, F., Tang, Y.-F., Li, C.-C., Chien, C., & Liu, J.-W. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.07.020 · Cited by 41
Ye, J.-J., Lin, H.-S., Kuo, A.-J., Leu, H., Chiang, P.-C., Huang, C., & Lee, M. (2011) · Journal of Infection · doi:10.1016/j.jinf.2011.08.001 · Cited by 41
Alternatives to carbapenems for infections caused by ESBL-producing Enterobacteriaceae
Pilmis, B., Parize, P., Zahar, J., & Lortholary, O. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-014-2094-y · Cited by 41
Mohammadi, M., Khayat, H., Sayehmiri, K., Soroush, S., Sayehmiri, F., Delfani, S., Bogdanović, L., & Taherikalani, M. (2017) · The Open Microbiology Journal · doi:10.2174/1874285801711010063 · Cited by 41
Zhao, C., Wang, X., Zhang, Y., Wang, R., Wang, Q., Li, H., & Wang, H. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-4093-1 · Cited by 41
Khil, P. P., Chiang, A. D., Ho, J., Youn, J.-H., Lemon, J. K., Gea‐Banacloche, J., Frank, K. M., Parta, M., Bonomo, R. A., & Dekker, J. P. (2019) · mBio · doi:10.1128/mbio.01822-19 · Cited by 41
Self-citationHamdi, A., Fida, M., Saleh, O. A., & Beam, E. N. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa008 · Cited by 41
Rapid Emergence of Resistance to Cefepime During Treatment
Limaye, A. P., Gautom, R., Black, D. J., & Fritsche, T. R. (1997) · Clinical Infectious Diseases · doi:10.1086/516917 · Cited by 40
Pournaras, S., Koumaki, V., Gennimata, V., Kouskouni, E. E., & Tsakris, A. (2015) · Advances in experimental medicine and biology · doi:10.1007/5584_2015_5001 · Cited by 40
Shortridge, D., Pfaller, M. A., Castanheira, M., & Flamm, R. K. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2018.05.011 · Cited by 40
Lob, S. H., DePestel, D. D., DeRyke, C. A., Kazmierczak, K. M., Young, K., Motyl, M. R., & Sahm, D. F. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab320 · Cited by 40
Yu, V. L., Felegie, T. P., Vee, R. B., Pasculle, A. W., & Taylor, F. H. (1980) · The Journal of Infectious Diseases · doi:10.1093/infdis/142.4.602 · Cited by 39
Gaibani, P., Bovo, F., Bussini, L., Lazzarotto, T., Amadesi, S., Bartoletti, M., Viale, P., & Ambretti, S. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac100 · Cited by 39
Sreenivasan, P., Sharma, B., Kaur, S., Rana, S., Biswal, M., Ray, P., & Angrup, A. (2022) · The Journal of Antibiotics · doi:10.1038/s41429-022-00537-3 · Cited by 39
Hernández‐Torres, A., García‐Vázquez, E., Gómez, J., Canteras, M., Ruiz, J., & Yagüe, G. (2011) · Medicina Clínica · doi:10.1016/j.medcli.2011.06.024 · Cited by 38
Chaubey, V. P., Pitout, J. D. D., Dalton, B., Gregson, D. B., Ross, T., & Laupland, K. B. (2014) · BMC Infectious Diseases · doi:10.1186/s12879-014-0647-4 · Cited by 38
Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam
Jaruratanasirikul, S., Wongpoowarak, W., Aeinlang, N., & Jullangkoon, M. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00342-13 · Cited by 38
Kang, C.-H., Tsai, C., Wu, T.-H., Wu, H.-Y., Chung, M., Chen, C., Huang, Y., Liu, S., Liao, D., Niu, C.-K., et al. (2013) · Pediatric Pulmonology · doi:10.1002/ppul.22750 · Cited by 38
Qvist, N., Warren, B., Leister-Tebbe, H. K., Zito, E. T., Pedersen, R. D., McGovern, P. C., & Babinchak, T. (2012) · Surgical Infections · doi:10.1089/sur.2011.048 · Cited by 38
Joly‐Guillou, M., Wolff, M., Farinotti, R., Bryskier, A., & Carbon, C. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.5.827 · Cited by 38
Chen, I. H., Kidd, J. M., Abdelraouf, K., & Nicolau, D. P. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01558-19 · Cited by 38
Lin, Q., Zou, H., Chen, X., Wu, M., Ma, D., Yu, H., Niu, S., & Huang, S. (2021) · BMC Microbiology · doi:10.1186/s12866-021-02108-2 · Cited by 38
Maraki, S., Mavromanolaki, V. E., Magkafouraki, E., Moraitis, P., Stafylaki, D., Kasimati, A., & Scoulica, E. V. (2021) · Infection · doi:10.1007/s15010-021-01735-1 · Cited by 38
Zheng, G., Cai, J., Zhang, L., Chen, D., Wang, L., Qiu, Y., Deng, H., Bai, H., Bian, X., & He, J. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00682-0 · Cited by 38
Montaña, S., Vilacoba, E., Traglia, G. M., Almuzara, M. N., Pennini, M., Fernández, A., Sucari, A., Centrón, D., & Ramirez, M. S. (2015) · Current Microbiology · doi:10.1007/s00284-015-0829-3 · Cited by 37
Wei, C., Ni, W., Cai, X., & Cui, J. (2015) · Scandinavian Journal of Infectious Diseases · doi:10.3109/23744235.2015.1064542 · Cited by 37
Abdul‐Mutakabbir, J. C., Yim, J., Nguyen, L., Maassen, P. T., Stamper, K. C., Shiekh, Z., Kebriaei, R., Shields, R. K., Castanheira, M., Kaye, K. S., et al. (2021) · Antibiotics · doi:10.3390/antibiotics10070880 · Cited by 37
NDM-35-Producing ST167 Escherichia coli Highly Resistant to β-Lactams Including Cefiderocol
Poirel, L., de la Rosa, J. M. O., Sakaoglu, Z., Kusaksizoglu, A., Sadek, M., & Nordmann, P. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00311-22 · Cited by 37
Girlich, D., Naas, T., Bellais, S., Poirel, L., Karim, A., & Nordmann, P. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.11.3220-3223.2000 · Cited by 36
Inhaled Colistin for Treatment of Pneumonia due to Colistin-Only-SusceptibleAcinetobacter baumannii
Choi, H. K., Kim, Y. K., Kim, H. Y., & Uh, Y. (2013) · Yonsei Medical Journal · doi:10.3349/ymj.2014.55.1.118 · Cited by 36
Cowart, M. C., & Ferguson, C. L. (2020) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000857 · Cited by 36
Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients
Falcone, M., Menichetti, F., Cattaneo, D., Tiseo, G., Baldelli, S., Galfo, V., Leonildi, A., Tagliaferri, E., Paolo, A. D., & Pai, M. P. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa549 · Cited by 36
Yang, T.-Y., Hsieh, Y., Kao, L.-T., Liu, G. H., Lian, S.-H., Wang, L., Lin, I., Wang, H.-Y., Tseng, S., & Lu, P. (2021) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2021.02.001 · Cited by 36
Pfaller, M. A., Huband, M. D., Shortridge, D., & Flamm, R. K. (2021) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2021.09.011 · Cited by 36
Lee, N., Huang, W.-H., Tsui, K.-C., Hsueh, P., & Ko, W. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.12.008 · Cited by 35
Ko, J., Lee, N. R., Joo, E., Moon, S., Choi, J. ‐., Park, D. A., & Peck, K. R. (2017) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-017-3133-2 · Cited by 35
Li, S., Jia, X., Li, C., Zou, H., Liu, H., Guo, Y., & Zhang, L. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s174876 · Cited by 35
Martínez-Servat, S., Yero, D., Huedo, P., Marquez, R., Molina, G., Daura, X., & Gibert, I. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02871 · Cited by 35
Karlowsky, J. A., Lob, S. H., Kazmierczak, K. M., Young, K., Motyl, M. R., & Sahm, D. F. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.10.022 · Cited by 35
Gajdács, M. (2020) · Antibiotics · doi:10.3390/antibiotics9040153 · Cited by 35
Castanheira, M., Doyle, T. B., Hubler, C. M., Sader, H. S., & Mendes, R. E. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106011 · Cited by 35
Hsieh, T.-C., Chen, F.-L., Ou, T.-Y., Jean, S., & Lee, W. (2014) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2014.08.009 · Cited by 34
Unbound fraction of ertapenem in intensive care unit patients
Liebchen, U., Kratzer, A., Wicha, S. G., Kees, F., Kloft, C., & Kees, M. G. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku226 · Cited by 34
Sader, H. S., Castanheira, M., Farrell, D. J., Flamm, R. K., & Jones, R. N. (2015) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2015.06.008 · Cited by 34
Huband, M. D., Castanheira, M., Flamm, R. K., Farrell, D. J., Jones, R. N., & Sader, H. S. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03056-15 · Cited by 34
Flamm, R. K., Castanheira, M., Streit, J. M., & Jones, R. N. (2016) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2016.03.019 · Cited by 34
Araoka, H., Baba, M., Okada, C., Abe, M., Kimura, M., & Yoneyama, A. (2017) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2017.02.020 · Cited by 34
Wu, C.-J., Lu, H.-F., Lin, Y.-T., Zhang, M.-S., Li, L.-H., & Yang, T. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00822 · Cited by 34
Boulant, T., Jousset, A. B., Bonnin, R. A., Barrail‐Tran, A., Borgel, A., Oueslati, S., Naas, T., & Dortet, L. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01637-19 · Cited by 34
Cheng, J., Yan, J., Reyna, Z., Slarve, M. J., Lu, P., Spellberg, B. J., & Luna, B. M. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02204-20 · Cited by 34
Tumbarello, M., Raffaelli, F., Cascio, A., Falcone, M., Signorini, L., Mussini, C., Rosa, F. G. D., Losito, A. R., PASCALE, G. D., Pascale, R., et al. (2022) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlac022 · Cited by 34
Sutherland, C. A., Verastegui, J. E., & Nicolau, D. P. (2016) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-016-0155-z · Cited by 33
Ren, H., Li, X., Ni, Z., Niu, J., Cao, B., Xu, J., Cheng, H., Tu, X., Ren, A.-M., Hu, Y., et al. (2017) · International Urology and Nephrology · doi:10.1007/s11255-017-1507-0 · Cited by 33
Use of colistin in treating multi-resistant Gram-negative organisms in a specialised burns unit
Ganapathy, H., Pal, S. K., Teare, L., & Dziewulski, P. G. (2009) · Burns · doi:10.1016/j.burns.2009.07.010 · Cited by 32
Castanheira, M., Arends, S. J. R., Davis, A. P., Woosley, L. N., Bhalodi, A. A., & MacVane, S. H. (2018) · mSphere · doi:10.1128/msphere.00408-18 · Cited by 32
Cefiderocol: the Trojan horse has arrived but will Troy fall?
Heil, E. L., & Tamma, P. D. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30828-8 · Cited by 32
Self-citationAlmangour, T. A., Aljabri, A. K., Musawa, M. A., Almohaizeie, A., Almuhisen, S., Damfu, N., Alfozan, A., Alraddadi, B. M., Alattas, M., Qutub, M., et al. (2022) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2022.01.023 · Cited by 32
Penetration of Minocycline Hydrochloride into Lung Tissue and Sputum
Watanabe, A., Watanabe, A., Anzai, Y., Anzai, Y., Niitsuma, K., Niitsuma, K., Saito, M., Saito, M., Yanase, K., Yanase, K., et al. (2000) · Chemotherapy · doi:10.1159/000048494 · Cited by 31
Watson, L. S., Esterly, J. S., Jensen, A. O., Postelnick, M. J., Aguirre, A. L., & McLaughlin, M. M. (2017) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2017.09.015 · Cited by 31
Arakawa, S., Kawahara, K., Kawahara, M., Yasuda, M., Fujimoto, G., Sato, A., Yokokawa, R., Yoshinari, T., Rhee, E. G., & Aoyama, N. (2018) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2018.10.009 · Cited by 31
Gomis-Font, M. A., Cabot, G., López-Argüello, S., Zamorano, L., Juan, C., Moyá, B., & Oliver, A. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab496 · Cited by 31
Sader, H. S., Castanheira, M., Flamm, R. K., & Jones, R. N. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00405-16 · Cited by 30
Atkin, S. D., Abid, S., Foster, M., Bose, M., Keller, A. E., Hollaway, R., Sader, H. S., Greenberg, D. E., Finklea, J. D., Castanheira, M., et al. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s173804 · Cited by 30
So, W., Shurko, J. F., Galega, R., Quilitz, R. E., Greene, J. N., & Lee, G. C. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky393 · Cited by 30
Sieswerda, E., van den Brand, M., van den Berg, R. B., Sträter, J., Schouls, L. M., van Dijk, K., & Budding, A. E. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz495 · Cited by 30
Current evidence for therapy of ceftriaxone-resistant Gram-negative bacteremia
Paterson, D. L., Henderson, A., & Harris, P. N. A. (2019) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000623 · Cited by 30
Karlowsky, J. A., Lob, S. H., Young, K., Motyl, M. R., & Sahm, D. F. (2021) · BMC Microbiology · doi:10.1186/s12866-021-02135-z · Cited by 30
ten Doesschate, T., Kuiper, S., van Nieuwkoop, C., Hassing, R. J., Ketels, T., van Mens, S. P., van den Bijllaardt, W., van der Bij, A. K., Geerlings, S. E., Koster, A., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab934 · Cited by 30
Chou, A., Welch, E., Hunter, A. S., & Trautner, B. W. (2022) · Drugs · doi:10.1007/s40265-022-01676-5 · Cited by 30
Tamma, P. D., Bergman, Y., Jacobs, E. B., Lee, J. H., Lewis, S., Cosgrove, S. E., & Simner, P. J. (2022) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2022.161 · Cited by 30
Self-citationUnderwood, S. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh235 · Cited by 29
Distressing Side-Effects of Minocycline Hydrochloride
Fanning, W. L. (1976) · Archives of Internal Medicine · doi:10.1001/archinte.1976.03630070009005 · Cited by 29
696. Mechanism of Cefiderocol high MIC mutants obtained in non-clinical FoR studies
Ito, A., Nishikawa, T., Ishii, R., Kuroiwa, M., Ishioka, Y., Kurihara, N., Sakikawa, I., Ota, T., Rokushima, M., Tsuji, M., et al. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy210.703 · Cited by 29
Sader, H. S., Carvalhaes, C. G., Streit, J. M., Doyle, T. B., & Castanheira, M. (2020) · Microbial Drug Resistance · doi:10.1089/mdr.2020.0217 · Cited by 29
Bhatnagar, A. S., Ransom, E. M., Machado, M.-J., Boyd, S., Reese, N., Anderson, K. F., Lonsway, D. R., Elkins, C. A., Rasheed, J. K., Patel, J. B., et al. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa531 · Cited by 29
Khan, A., Pettaway, C. H., Bard, J. D., Arias, C. A., Bhatti, M. M., & Humphries, R. M. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02631-20 · Cited by 29
Fratoni, A. J., Nicolau, D. P., & Kuti, J. L. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab344 · Cited by 29
Petraitis, V., Petraitienė, R., Kavaliauskas, P., Naing, E., Garcia, A. J., Georgiades, B. N., ECHOLS, R. M., Bonomo, R. A., Yamano, Y., Satlin, M. J., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00618-22 · Cited by 29
Self-citationKiffer, C. R. V., Kuti, J. L., Eagye, K. J., Mendes, C., & Nicolau, D. P. (2006) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.05.031 · Cited by 28
Fatal Acinetobacter baumannii Infection with Discordant Carbapenem Susceptibility
Lesho, E. P., Wortmann, G. W., Moran, K., & Craft, D. W. (2005) · Clinical Infectious Diseases · doi:10.1086/432623 · Cited by 28
Kurpiel, P. M., & Hanson, N. D. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr479 · Cited by 28
Mendes, R. E., Castanheira, M., Woosley, L. N., Stone, G. G., Bradford, P. A., & Flamm, R. K. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02655-18 · Cited by 28
Venditti, C. C., Nisii, C., D’Arezzo, S., Vulcano, A., Capone, A., Antonini, M., Ippolito, G., & Di, A. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s207993 · Cited by 28
Tamma, P. D., & Humphries, R. M. (2021) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlab019 · Cited by 28
Self-citationSader, H. S., Duncan, L. R., Doyle, T. B., & Castanheira, M. (2021) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlab126 · Cited by 28
Martín‐Loeches, I., Timsit, J., Kollef, M. H., Wunderink, R. G., Shime, N., Nováček, M., Kivistik, Ü., Réa-Neto, Á., Bruno, C. J., Huntington, J. A., et al. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab494 · Cited by 28
Belati, A., Bavaro, D. F., Diella, L., Gennaro, N. D., Gennaro, F. D., & Saracino, A. (2022) · Antibiotics · doi:10.3390/antibiotics11030373 · Cited by 28
Lasko, M. J., Tabor-Rennie, J. L., Nicolau, D. P., & Kuti, J. L. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac304 · Cited by 28
Musher, D. M., Minuth, J. N., Thorsteinsson, S. B., & Holmes, T. (1975) · The Journal of Infectious Diseases · doi:10.1093/infdis/131.supplement.s40 · Cited by 27
Kim, S. A., Altshuler, J., Paris, D., & Fedorenko, M. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.09.013 · Cited by 27
Cheng, M. P., Lee, R. S., Cheng, A. P., l’Étoile-Morel, S. D., Demir, K. K., Yansouni, C. P., Harris, P. N. A., McDonald, E. G., & Lee, T. C. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz248 · Cited by 27
Xiao, T., Yang, K., Zhou, Y., Zhang, S., Ji, J., Ying, C., Shen, P., & Xiao, Y. (2019) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-019-0599-y · Cited by 27
Mularoni, A., Mezzatesta, M. L., Pilato, M., Medaglia, A. A., Cervo, A., Bongiorno, D., Aprile, A., Luca, A., Stefani, S., & Grossi, P. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.05.085 · Cited by 27
Research works printed but not linked: 10
- Clinical and Laboratory Standards Institute, 2023, M100: performance standards for antimicrobial susceptibility testing
- Sharara, 2019, Is piperacillin-tazobactam effective for the treatment of pyelonephritis caused by ESBL-producing organisms?, Clin Infect Dis, 71
- Centers for Disease Control and Prevention, 2015, Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE): November 2015 update—CRE toolkit
- Chen, 2022, Efficacy and safety of ceftazidime-avibactam for the treatment of carbapenem-resistant enterobacterales bloodstream infection: a systematic review and meta-analysis, Microbiol Spectr, 10
- Shields, 2017, Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections, Antimicrob Agents Chemother, 61
- Li, 2022, Increased expression and amplification of blaKPC-2 contributes to resistance to ceftazidime/avibactam in a sequence type 11 carbapenem-resistant Klebsiella pneumoniae strain, Microbiol Spectr, 10
- Morrissey, 2020, In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017, Antimicrob Agents Chemother, 64
- Karlowsky, 2020, In vitro activity of imipenem/relebactam and ceftolozane/tazobactam against clinical isolates of gram-negative bacilli with difficult-to-treat resistance and multidrug-resistant phenotypes—SMART United States 2015–2017, Clin Infect Dis, 72
- Skoglund, 2018, In vivo resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa arising by AmpC- and non-AmpC-mediated pathways, Case Rep Infect Dis, 2018
- Cheah, 2015, New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection, J Antimicrob Chemother, 70, 3291
Cited by
ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics
Miller, W. R., & Arias, C. A. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01054-w · Cited by 862
“…(for which sulbactam is the active component against A. baumannii PBP3) is the current preferred backbone of therapy, with evidence of improved outcomes when used at a high dose (≥9 g per day of sulbactam) in combination with another active agent in mostly observational studies 180 .”
Pseudomonas aeruginosa: Infections, Animal Modeling, and Therapeutics
Wood, S. J., Kuzel, T. M., & Shafikhani, S. H. (2023) · Cells · doi:10.3390/cells12010199 · Cited by 254
Hypervirulent and carbapenem-resistant Klebsiella pneumoniae: A global public health threat
Lei, T.-Y., Liao, B.-B., Yang, L.-R., Wang, Y., & Chen, X.-B. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127839 · Cited by 174
Kaye, K. S., Belley, A. C., Barth, P., Lahlou, O., Knechtle, P., Motta, P., & Vélicitat, P. (2022) · JAMA · doi:10.1001/jama.2022.17034 · Cited by 147
Carmeli, Y., Cisneros, J. M., Paul, M., Daikos, G. L., Wang, M., Torre‐Cisneros, J., Singer, G., Titov, I., Gumenchuk, I., Zhao, Y., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00499-7 · Cited by 146
Metadata
- Authors
- Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J.
- Affiliations
- Johns Hopkins University (US)
- University of Michigan (US)
- University Hospitals of Cleveland (US)
- University of Virginia (US)
- Department of Medicine, University of North Carolina School of Medicine , Chapel Hill, North Carolina ,
- University of Pittsburgh (US)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-07-18
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W4384665204
- Cited by
- 740
- References
- 697
- Citations by year
- 2026: 134 · 2025: 159 · 2024: 335 · 2023: 84
- FWCI
- 60.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- AstraZeneca
- Infectious Diseases Society of America
- Case Western Reserve University
- Medicines Company
- Melinta Therapeutics
- Entasis Therapeutics
- European Society of Clinical Microbiology and Infectious Diseases (ESCMID 2022)
- Universidade Federal do Rio Grande do Sul
- Shionogi
- Basilea Pharmaceutica
- Wockhardt
- National Institutes of Health
- Centers for Disease Control and Prevention
- Allergan
- Topics
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Infections and bacterial resistance
- Keywords
- antimicrobial resistance, gram-negative bacterial infection, extended-spectrum beta-lactamase, AmpC beta-lactamase, carbapenem-resistant Enterobacteriaceae, Pseudomonas aeruginosa, carbapenem-resistant Acinetobacter baumannii, Stenotrophomonas maltophilia, antimicrobial therapy, empirical treatment, oral therapy, treatment duration, pediatric infection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.